IAG and Resonance Health form global imaging partnership

Image Analysis Group and Resonance Health have launched a global strategic partnership to combine regulatory-cleared MRI endpoints with AI-enabled trial imaging infrastructure. The alliance is aimed at obesity, metabolic and liver-disease studies, with an added Australian trial delivery pathway that could help sponsors run studies more efficiently.

Why it matters: - The partnership gives clinical trial sponsors a single imaging pathway that spans trial design, image acquisition, quantitative analysis, central review and reporting. - The deal is aimed at obesity and metabolic trials, where sponsors need to measure body composition changes, not just body weight. - The combination also broadens access to regulated imaging endpoints for liver, iron, fat and muscle-related studies.

What happened: - Image Analysis Group (IAG) and Resonance Health announced a global strategic partnership on September 23, 2026. - IAG is adding Resonance Health’s quantitative MRI endpoints to global trial strategies and proposals. - Resonance Health is gaining access to IAG’s imaging infrastructure, global reader network and DYNAMIKA™ platform for multi-modality studies. - The partnership links global imaging strategy with Australian trial delivery, including local sponsorship and Australian clinical trial sites.

The details: - IAG’s DYNAMIKA™ platform, AI capabilities and global reader network are being combined with Resonance Health’s regulatory-cleared imaging endpoints. - Resonance Health’s endpoints include FerriScan® and HepaFatScan®, with coverage across liver iron, liver fat, cardiac iron and emerging body-composition uses. - IAG’s platform has supported more than 700 clinical trials globally. - The joint offering includes DXA body-composition and muscle imaging workflows from IAG and quantitative MRI capabilities from Resonance Health. - Resonance Health’s MRI measures include visceral and subcutaneous fat, liver fat, muscle mass and muscle quality measures in development. - Resonance Health says its imaging technologies are cleared in the United States, Europe, the United Kingdom and Australia. - Resonance Health operates under an ISO 13485-certified quality management system and a specialist imaging core laboratory. - Resonance Health’s development pipeline includes an MRI liver fibrosis device programme supported by an ongoing clinical trial. - In Australia, Resonance Health operates owned TrialsWest trial sites and a local-sponsor model for overseas sponsors. - The companies expect the partnership to support sponsors in obesity and metabolic disease, haemoglobinopathies and iron overload disorders, MASH/MASLD, hepatology, oncology and musculoskeletal disease. - Initial engagements are planned across Europe, the United States, Australia and China. - IAG says its global reader network spans the UK, EU, USA, India, China and Australia. - IAG operates under 21 CFR Part 11, SOC 2 Type II and ISO 13485 frameworks.

Between the lines: - The deal reflects a push toward more detailed trial readouts in the GLP-1 era, when weight loss alone is not enough to show how a therapy changes fat, liver health and muscle. - For IAG, the partnership extends its imaging reach deeper into regulated MRI endpoints. - For Resonance Health, the alliance offers a larger international sponsor base and a route to scale recurring clinical-trial revenue. - Resonance Health said group revenue grew from $4 million in FY23 to $16 million in FY26 guidance.

What's next: - The companies plan to take the combined offering into sponsor discussions across multiple therapeutic areas and geographies. - Resonance Health said its portfolio is expanding from iron and liver fat toward fibrosis, body composition and muscle quality. - The companies flagged Australia’s R&D Tax Incentive as a possible benefit for eligible trial activities, but eligibility depends on individual circumstances. - Both companies cautioned that forward-looking statements are subject to risks and uncertainties.

The bottom line: - IAG and Resonance Health are trying to turn specialized imaging into a more integrated global trial platform, with obesity and metabolic studies as the clearest near-term use case.

More information